Fluorescent Indicators Distributed throughout the Pharmacophore of Cholecystokinin Provide Insights into Distinct Modes of Binding and Activation of Type A and B Cholecystokinin Receptors*

Ligand probes with fluorescent indicators positioned throughout the pharmacophoric domain can provide important insights into the molecular basis of receptor binding and activation as reflected in the microenvironment of each indicator while docked at a receptor. We developed three cholecystokinin-like probes with Aladan situated at the N terminus, in the mid-region, and at the C terminus (positions 24, 29, and 33, respectively). These were studied in solution and docked at type A and B cholecystokinin receptors. This study demonstrated clear differences in mechanisms of cholecystokinin binding and activation of these structurally related receptors with distinct agonist structure-activity relationships. The fluorescence characteristics of Aladan are highly sensitive to the polarity of its microenvironment. The mid-region probe was least accessible to the aqueous milieu as determined by fluorescence emission spectra and iodide quenching, which was not altered by changes in conformation from active to inactive. Accessibility of the N- and C-terminal probes was affected by receptor conformation. The position 24 probe was more easily quenched in the active than in the G protein-uncoupled conformation for both receptors. However, the position 33 probe docked at the type A cholecystokinin receptor was more easily quenched in the active conformation, whereas the same probe docked at the type B cholecystokinin receptor was more easily quenched in the inactive conformation. Fluorescence anisotropy and red edge excitation shift determinations confirmed these observations and supported the proposed movements. Although both type A and B cholecystokinin receptors bind cholecystokinin with high affinity, resulting in fully efficacious biological responses, these receptors utilize distinct molecular modes of binding.

[1]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[2]  L. Miller,et al.  Differential Spatial Approximation between Cholecystokinin Residue 30 and Receptor Residues in Active and Inactive Conformations , 2005, Molecular Pharmacology.

[3]  L. Miller,et al.  Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. , 2005, Biochemistry.

[4]  A. Chakrabarti,et al.  Effect of ionic strength on the organization and dynamics of tryptophan residues in erythroid spectrin: A fluorescence approach , 2005, Biopolymers.

[5]  L. Miller,et al.  Distinct Molecular Mechanisms for Agonist Peptide Binding to Types A and B Cholecystokinin Receptors Demonstrated Using Fluorescence Spectroscopy* , 2005, Journal of Biological Chemistry.

[6]  L. Miller,et al.  Key Differences in Molecular Complexes of the Cholecystokinin Receptor with Structurally Related Peptide Agonist, Partial Agonist, and Antagonist , 2004, Molecular Pharmacology.

[7]  L. Miller,et al.  Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.

[8]  A. Chakrabarti,et al.  Organization and dynamics of tryptophan residues in erythroid spectrin: Novel structural features of denatured spectrin revealed by the wavelength‐selective fluorescence approach , 2003, Protein science : a publication of the Protein Society.

[9]  A. D. Robertson,et al.  Illuminating proteins with Aladan's lamp , 2002, Nature Structural Biology.

[10]  Y. Jan,et al.  Probing Protein Electrostatics with a Synthetic Fluorescent Amino Acid , 2002, Science.

[11]  L. Miller,et al.  Environment and Mobility of a Series of Fluorescent Reporters at the Amino Terminus of Structurally Related Peptide Agonists and Antagonists Bound to the Cholecystokinin Receptor* , 2002, The Journal of Biological Chemistry.

[12]  T. Lybrand,et al.  Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. , 2002, Molecular pharmacology.

[13]  T. Lybrand,et al.  Refinement of the Structure of the Ligand-occupied Cholecystokinin Receptor Using a Photolabile Amino-terminal Probe* , 2001, The Journal of Biological Chemistry.

[14]  J. Rehfeld Cholecystokinin and panic disorder — three unsettled questions , 2000, Regulatory Peptides.

[15]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[16]  E. Kojro,et al.  Direct identification of the agonist binding site in the human brain cholecystokininB receptor. , 1999, Biochemistry.

[17]  J. Landers,et al.  Structurally Related Peptide Agonist, Partial Agonist, and Antagonist Occupy a Similar Binding Pocket within the Cholecystokinin Receptor , 1999, The Journal of Biological Chemistry.

[18]  T. Lybrand,et al.  Direct Identification of a Second Distinct Site of Contact between Cholecystokinin and Its Receptor* , 1998, The Journal of Biological Chemistry.

[19]  T. Lybrand,et al.  Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.

[20]  B. Maigret,et al.  Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin* , 1997, The Journal of Biological Chemistry.

[21]  L. F. Kolakowski,et al.  Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor. , 1996, Molecular pharmacology.

[22]  L. Miller,et al.  Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.

[23]  S. Silvente-Poirot,et al.  A Segment of Five Amino Acids in the Second Extracellular Loop of the Cholecystokinin-B Receptor Is Essential for Selectivity of the Peptide Agonist Gastrin* , 1996, The Journal of Biological Chemistry.

[24]  August B. Smit,et al.  Co-evolution of Ligand-Receptor Pairs in the Vasopressin/Oxytocin Superfamily of Bioactive Peptides (*) , 1996, The Journal of Biological Chemistry.

[25]  L. F. Kolakowski,et al.  The Role of the Cholecystokinin-B/Gastrin Receptor Transmembrane Domains in Determining Affinity for Subtype-selective Ligands(*) , 1995, The Journal of Biological Chemistry.

[26]  R. Campbell,et al.  Co-evolution of ligand-receptor pairs , 1994, Nature.

[27]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[28]  V. Mutt Additional observations on cholecystokinin and the vasoactive intestinal polypeptide , 1981, Peptides.

[29]  L. Miller,et al.  Preparation and characterization of a probe for the cholecystokinin octapeptide receptor, N alpha (125I-desaminotyrosyl)CCK-8, and its interactions with pancreatic acini. , 1981, The Journal of biological chemistry.

[30]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[31]  G. Weber,et al.  Synthesis and spectral properties of a hydrophobic fluorescent probe: 6-propionyl-2-(dimethylamino)naphthalene. , 1979, Biochemistry.

[32]  Amitabha Chattopadhyay,et al.  Exploring membrane organization and dynamics by the wavelength-selective fluorescence approach. , 2003, Chemistry and physics of lipids.

[33]  M. Fournié-Zaluski,et al.  [Enkephalin catabolism inhibitors and antalgics of the future: from preclinical research to clinical trials]. , 1999, Therapie.

[34]  Kolakowski Lf GCRDB: A G-PROTEIN-COUPLED RECEPTOR DATABASE , 1994 .